On August 24, PHARMARON fell 3.43% in regular trading, trading at HK$32.06, with turnover of approximately HK$40.6 million. The decline came as the broader CXO sector faced collective selling pressure.

On the news front, the Life Sciences Tools & Services sector saw widespread weakness, with peers Wuxi Biologics down 3.88%, Wuxi XDC down 3.98%, GenScript Biotech down 3.19%, and Wuxi AppTec down 2.24%, dragging down the entire CXO complex. While the company disclosed its interim results on August 20 showing revenue of RMB 7.595 billion (up 17.92% YoY), operating cash flow declined 23% YoY, and more than 10 institutions reduced their holdings during Q2, intensifying short-term selling pressure. Meanwhile, Morgan Stanley raised its target price to HK$35.6 with an Overweight rating post-results, but the broader sector downturn and profit-taking after the stock's significant prior rally appear to be outweighing the positive broker sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)